Carly Helfand

Biography for Carly Helfand

Carly Helfand, News Editor

Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at chelfand@fiercemarkets.com and follow her on Twitter at @CarlyHFierce.

Articles by Carly Helfand

Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything

After years of pinning its vaccine ambitions on meningitis B shot Bexsero, Novartis' FDA approval is here. But as it prepares to fork over the jab--along with the bulk of its vaccines business--to deal partner GlaxoSmithKline, there are other hurdles in the way of its success--including some new competition from Pfizer.

GSK to divest meningitis shots in exchange for EU clearance of Novartis deal

The European Commission has cleared GlaxoSmithKline's deal for most of Novartis' vaccines unit--on a couple of conditions.

Pfizer wins recommendation for Prevenar expansion in Europe

The European Medicines Agency accepted Pfizer's application to expand its label for blockbuster vaccine Prevenar 13 back in August, and so far, an advisory committee likes what it sees.

Disneyland measles outbreak adds fuel to heated anti-vaccination debate

The measles outbreak that began at Disneyland is spreading across California and beyond, and it's reigniting a heated debate over the anti-vaccination movement.

After rocky flu season, vaccinemakers may want to follow Novartis' lead

Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.

MSF urges GSK, Pfizer to slash pneumococcal vaccine prices

The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.

PaxVax ready to strike M&A deals that prove its sales model, CEO says

PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says.

China approves world's first inactivated Sabin polio vaccine

China's FDA has green-lighted the world's first Sabin strain inactivated polio vaccine--and a locally produced one, at that.

Pfizer developing cholesterol-fighting vaccine as part of PCSK9 'franchise'

PCSK9 drugs are the next big market waiting to happen, and with rivals Sanofi/Regeneron and Amgen ahead in the development race, Pfizer wants to make sure it can lock down a solid share of the market. So beyond in-development anti-cholesterol antibody bococizumab, it's working on a wider PCSK9 "franchise," R&D chief Mikael Dolsten said Tuesday at the JP Morgan Healthcare Conference--and that includes a vaccine.

Late-stage trials for Glaxo, Merck Ebola jabs could begin this month in West Africa

GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.